Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Zoetis Inc. (ZTS) — XLV Health Care · S&P 500 Profile |碩騰公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Zoetis Inc. (ZTS) — Business, History & S&P 500 Profile | 碩騰公司介紹

Zoetis Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #303 · 碩騰公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026
Financials: FY2025
MARKET CAP
$34.26B
Nov 3, 2026
S&P 500 WEIGHT
0.05%
Rank #303 · Nov 3, 2026
SECTOR RANK
#39
Health Care · Nov 3, 2026
S&P 500 RANK
#303
0.05% · Nov 3, 2026

SNAPSHOT

TickerZTS
CompanyZoetis Inc.
GICS sector / industryHealth Care (XLV) / Pharmaceuticals
S&P 500 rank (by weight)#303 · 0.05% (Nov 3, 2026)
Sector rank#39 of 60 in Health Care (Nov 3, 2026)
HeadquartersParsippany, New Jersey
Founded1952 (2013)
CEOKristin C. Peck (Chief Executive Officer)
Employees14,500 (2025)
Market cap$34.26B (Nov 3, 2026)
Share price$82.74 (Nov 3, 2026)
SEC filingsEDGAR — CIK 0001555280

WHAT IT DOES

Zoetis Inc. is the world's largest animal-health company, headquartered in Parsippany, New Jersey. It develops, manufactures and sells medicines, vaccines, diagnostics and genetic tests for pets and farm animals, a business that began in 1952 as Pfizer's animal-health division and became independent in 2013.

Its one-line model: sell innovative, patent-protected animal medicines through veterinarians and producers, led by companion-animal franchises — Simparica parasiticides, Apoquel and Cytopoint dermatology products, and the Librela and Solensia osteoarthritis antibodies. Companion animals supplied $6.59B of fiscal 2025 revenue of $9.47B.

Zoetis is a steady compounder: fiscal 2025 revenue rose to $9,467M from $9,256M, net income rose to $2,673M from $2,486M, and diluted EPS rose to $6.02 — growth led by pet care, partly offset by a decline in U.S. livestock revenue to $877M from $1,020M.

BUSINESS SEGMENTS

United StatesU.S. companion animal revenue of $4,220M and livestock revenue of $877M — fiscal 2025 segment revenue of $5,097M, about 54% of the total.
InternationalInternational companion animal revenue of $2,367M and livestock revenue of $1,887M — fiscal 2025 segment revenue of $4,254M.
Contract manufacturing & human healthContract manufacturing and human-health products (a legacy Pfizer activity) — fiscal 2025 revenue of $116M.

HISTORY

YearMilestone
1952Zoetis's origins: Pfizer builds its agricultural and animal-health division, the business that becomes Zoetis.
2013Zoetis lists on the NYSE in February 2013 in the largest U.S. IPO since Facebook at the time; Pfizer completes the separation in June 2013 through an exchange offer.
2018Zoetis acquires Abaxis for about $2.0B, adding point-of-care veterinary diagnostics.
2020Kristin C. Peck becomes chief executive officer (January 1, 2020).
2023Librela — the first monoclonal antibody for osteoarthritis pain in dogs — launches in the United States, extending the pet-dermatology and pain franchises.
2025Revenue reaches $9.47B with net income of $2.67B, companion animals supplying about 70% of revenue.

COMPETITIVE POSITION

  • Market leadership: the largest animal-health company globally, with leading positions in pet parasiticides, dermatology and pain, ahead of Elanco, Merck Animal Health and Boehringer Ingelheim Animal Health.
  • Innovation-led franchises: Simparica Trio, Apoquel, Cytopoint and the Librela/Solensia antibodies are patent-protected, vet-channel brands with multi-year growth runways.
  • Diversification: revenue splits between companion animals (about 70%) and livestock, and between the U.S. ($5,097M) and international markets ($4,254M).
  • Diagnostics adjacency: the Abaxis point-of-care platform and reference labs tie instruments and consumables into veterinary clinics.

FINANCIAL SNAPSHOT

Total revenue$9.47B (FY2025 revenue)
Income before income taxes$3.36B (FY2025 pre-tax income)
Net income$2.67B (FY2025 net income)
Diluted EPS$6.02 (FY2025 diluted EPS)
Source: Zoetis fiscal 2025 Form 10-K (year ended December 31, 2025), figures via SEC EDGAR company data, corroborated by the Wikipedia company profile (revenue $9.47B, net income $2.67B, employees 14,500). Exact figures: revenue $9,467M; income before income taxes $3,360M; net income $2,673M. Zoetis does not present a separate operating-income subtotal in the lines used here, so the pre-tax figure is shown and labelled as such rather than estimated.

KEY RISKS

  • Patent and competition risk in key franchises: Simparica and dermatology products face rival launches and, over time, generic pressure as patents expire.
  • Librela scrutiny: post-launch adverse-event reports and regulator correspondence (including a 2024 FDA letter to veterinarians) keep the OA antibody franchise under a safety spotlight.
  • Livestock cyclicality: cattle and swine economics, feed costs and disease outbreaks drive producer demand; U.S. livestock revenue fell in fiscal 2025.
  • Currency: about 45% of revenue is international, exposing results to dollar strength.
  • Customer consolidation: corporate veterinary groups and distributors gain bargaining power over manufacturers.

WHY IT MATTERS FOR THE S&P 500

Zoetis is a small-weight health-care constituent: rank #303 by weight at 0.05% as of Nov 3, 2026, and #39 in Health Care. As the index's only pure-play animal-health major, it isolates pet-care and livestock economics from human pharma.

SOURCES & METHODOLOGY

Financials, segments, headquartersZoetis Inc. fiscal 2025 Form 10-K data via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and employees via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 3, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$34.26B (Slickcharts, Nov 3, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

ZTS

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ZTS
公司Zoetis Inc.(碩騰)
GICS 板塊/行業醫療保健(XLV)/製藥
標普500排名(按權重)#303 · 0.05%(Nov 3, 2026)
板塊內排名醫療保健 #39(共 60 家)(Nov 3, 2026)
總部美國新澤西州帕西波尼
成立1952年(2013年獨立)
執行長Kristin C. Peck(執行長)
員工14,500(2025年)
市值$34.26B(Nov 3, 2026)
股價$82.74(Nov 3, 2026)
SEC 申報EDGAR — CIK 0001555280

業務概覽

碩騰是全球最大的動物保健公司,總部位於美國新澤西州帕西波尼。公司研發、生產與銷售寵物及農場動物的藥物、疫苗、診斷產品與基因檢測,業務源於 1952 年輝瑞的動物保健部門,2013 年獨立。

其一句話商業模式是:透過獸醫與生產者銷售具專利保護的創新動物藥物,以伴侶動物系列領軍——Simparica 驅蟲藥、Apoquel 與 Cytopoint 皮膚科產品,以及 Librela 與 Solensia 骨關節炎抗體藥。伴侶動物於 2025 財年收入 94.67 億美元中佔 65.87 億美元。

碩騰是穩定的複合增長者:2025 財年收入由 92.56 億美元增至 94.67 億美元,淨利潤由 24.86 億美元增至 26.73 億美元,稀釋 EPS 升至 6.02 美元——增長由寵物護理帶動,部分被美國畜禽收入由 10.20 億美元降至 8.77 億美元抵銷。

業務板塊

美國美國伴侶動物收入 42.20 億美元、畜禽收入 8.77 億美元——2025 財年板塊收入 50.97 億美元,約佔總額 54%。
國際國際伴侶動物收入 23.67 億美元、畜禽收入 18.87 億美元——2025 財年板塊收入 42.54 億美元。
合約製造與人類健康合約製造與人類健康產品(源於輝瑞的遺留業務)——2025 財年收入 1.16 億美元。

歷史

年份里程碑
1952碩騰的源頭:輝瑞建立其農業與動物保健部門,即日後成為碩騰的業務。
2013碩騰於 2013 年 2 月在紐約證券交易所上市,是當時自 Facebook 以來最大規模的美國 IPO;輝瑞於 2013 年 6 月透過換股要約完成分拆。
2018碩騰以約 20 億美元收購 Abaxis,加入即時獸醫診斷業務。
2020Kristin C. Peck 出任執行長(2020 年 1 月 1 日)。
2023Librela——首個用於犬隻骨關節炎疼痛的單株抗體藥——在美國推出,擴展寵物皮膚科與疼痛系列。
2025收入達 94.67 億美元,淨利潤 26.73 億美元,伴侶動物佔收入約 70%。

競爭地位

  • 市場領導地位:全球最大的動物保健公司,在寵物驅蟲、皮膚科與疼痛領域領先 Elanco、Merck Animal Health 與 Boehringer Ingelheim Animal Health。
  • 創新主導系列:Simparica Trio、Apoquel、Cytopoint 與 Librela/Solensia 抗體藥是具專利保護、經獸醫渠道銷售的品牌,具多年增長空間。
  • 多元化:收入分佈於伴侶動物(約 70%)與畜禽之間,以及美國(50.97 億美元)與國際市場(42.54 億美元)之間。
  • 診斷相鄰業務:Abaxis 即時診斷平台與參考實驗室將儀器與耗材嵌入獸醫診所。

財務快照

總收入$9.47B(FY2025 收入)
稅前利潤$3.36B(FY2025 稅前利潤)
淨利潤$2.67B(FY2025 淨利潤)
稀釋 EPS$6.02(FY2025 稀釋 EPS)
來源:碩騰 2025 財年 Form 10-K(截至 2025 年 12 月 31 日),數字經 SEC EDGAR 公司數據,並經維基百科公司資料核對(收入 94.7 億美元、淨利潤 26.7 億美元、員工 14,500 人)。精確數字:收入 94.67 億美元;稅前利潤 33.60 億美元;淨利潤 26.73 億美元。碩騰在本文所用報表行中未單列營業利潤小計,故列示稅前利潤並如實標明,而非估算。

主要風險

  • 關鍵系列的專利與競爭風險:Simparica 與皮膚科產品面對對手推出新品,長遠而言專利到期後有學名藥壓力。
  • Librela 審視:上市後不良事件報告與監管函件(包括 2024 年 FDA 致獸醫的信函)令骨關節炎抗體系列持續處於安全聚光燈下。
  • 畜禽週期性:牛與豬的經濟效益、飼料成本與疾病爆發主導生產者需求;美國畜禽收入於 2025 財年下跌。
  • 貨幣:約 45% 收入來自國際市場,業績受美元強弱影響。
  • 客戶整合:企業獸醫集團與分銷商對製造商的議價能力上升。

對標普500的重要性

碩騰是權重較小的醫療保健成分股:按權重排名 #303,權重 0.05%(以 2026 年 11 月 3 日為準),醫療保健板塊內排名 #39。作為指數中唯一的純動物保健大型股,它將寵物護理與畜禽經濟從人類製藥中分離出來。

來源與方法

財務、板塊、總部碩騰 2025 財年 Form 10-K 數據,經 SEC EDGAR(見財務快照附註);總部、執行長與員工經 Form 10-K 及維基百科公司資料
指數權重與排名Slickcharts 標普 500 權重,Nov 3, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$34.26B(StockAnalysis,Nov 3, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

ZTS

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ZTS
Data as of Nov 3, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Axon Enterprise, Inc. (AXON) — XLI Industrials · S&P 500 Profile |Axon公司介紹Next · Mettler-Toledo International Inc. (MTD) — XLV Health Care · S&P 500 Profile |梅特勒-托利多公司介紹

Entered 2026-11-03 10:52 · updated 2026-11-15 00:21 · rev 6